Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ hematopoietic progenitor cells (Stanford University)
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Purified CD34+ hematopoietic progenitor cells (HSPCs) are the primary component of a specialized T-cell depleted allogeneic hematopoietic cell transplantation (HCT) regimen developed by Stanford University. This therapeutic approach is designed for patients with advanced hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML). The protocol involves the infusion of highly purified CD34+ stem cells to provide hematopoietic recovery, followed by the sequential or co-infusion of donor-derived regulatory T cells (Tregs) to suppress graft-versus-host disease (GVHD) and conventional T cells (Tcons) to facilitate immune reconstitution and provide a graft-versus-leukemia (GVL) effect. By depleting the initial graft of non-specific T cells and adding back defined subsets, the therapy aims to improve transplant outcomes and reduce treatment-related mortality.
- Other names
- Purified CD34+ hematopoietic progenitor cellsCD34+ HSPCT-cell depleted hematopoietic stem cell graft
Beyond the preview
Go deeper on CD34+ hematopoietic progenitor cells (Stanford University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ hematopoietic progenitor cells (Stanford University).